A-423,579 is one of a range of histamine antagonists developed by Abbott Laboratories which are selective for the H3 subtype, and have stimulant and anorectic effects in animal studies making them potentially useful treatments for obesity. A-423,579 has improved characteristics over earlier drugs in the series with both high efficacy and low toxicity in studies on mice, and is currently in clinical development.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.